Medicare will soon cover obesity drugs, but many seniors may not know
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news…
GLP-1 weight loss pills may be bad thing for job insurance coverage
The new GLP-1 pills are likely to boost consumer demand for these popular weight-loss drugs. But it could…
UPS to invest $48 million in cold facilities amid GLP-1 boom
United Parcel Service (UPS) trucks are parked at a UPS drop yard on Oct. 28, 2025 in Vernon,…
Novo Nordisk, Eli Lilly roll out obesity pills, prepare for Medicare coverage
Novo Nordisk and Eli Lilly took their GLP-1 pill battle to the preeminent obesity meeting this weekend as…
Weight loss drug maker stock sinks 25% as safety data spooks investors
Shares of weight loss drug maker Zealand Pharma plummeted as much as 26% on Monday after new data…
CVS restores Zepbound coverage, adds Eli Lilly’s obesity pill Foundayo
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on…
Global market reordering is accelerating as the AI rally gains pace
The Wall Street bull stands in the financial district near the New York Stock Exchange on Nov. 18,…
New data boosts our confidence in Lilly’s obesity pill. Plus, Google’s new AI
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
Novo Nordisk releases new high-dose Wegovy data
A Wegovy injection pen shown in Waterbury, Vermont, April 28, 2025. Shelby Knowles | Bloomberg | Getty Images…
Novo Nordisk faces Ozempic generics in Canada
Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood…
Novo Nordisk CEO Mike Doustdar says Ozempic maker looking for deals
Novo Nordisk is looking for deals more than ever before, the CEO of the Danish drugmaker said in…
Novo Nordisk Wegovy pill beating Eli Lilly Foundayo early
Wegovy semaglutide tablets. Michael Siluk | Universal Images Group | Getty Images When the Wegovy pill launched in…